Syzygium cumini ameliorates insulin resistance and β-cell dysfunction via modulation of PPAR, dyslipidemia, oxidative stress, and TNF-α in type 2 diabetic rats

J Pharmacol Sci. 2012;119(3):205-13. doi: 10.1254/jphs.11184fp. Epub 2012 Jun 21.

Abstract

Syzygium cumini (SC) is well known for its anti-diabetic potential, but the mechanism underlying its amelioration of type 2 diabetes is still elusive. Therefore, for the first time, we investigated whether SC aqueous seed extract (100, 200, or 400 mg/kg) exerts any beneficial effects on insulin resistance (IR), serum lipid profile, antioxidant status, and/or pancreatic β-cell damage in high-fat diet / streptozotocin-induced (HFD-STZ) diabetic rats. Wistar albino rats were fed with HFD (55% of calories as fat) during the experiment to induce IR and on the 10th day were injected with STZ (40 mg/kg, i.p.) to develop type 2 diabetes. Subsequently, after confirmation of hyperglycemia on the 14th day (fasting glucose level > 13.89 mM), diabetic rats were treated with SC for the next 21 days. Diabetic rats showed increased serum glucose, insulin, IR, TNF-α, dyslipidemia, and pancreatic thiobarbituric acid-reactive substances with a concomitant decrease in β-cell function and pancreatic superoxide dismutase, catalase, and glutathione peroxidase antioxidant enzyme activities. Microscopic examination of their pancreas revealed pathological changes in islets and β-cells. These alterations reverted to near-normal levels after treatment with SC at 400 mg/kg. Moreover, hepatic tissue demonstrated increased PPARγ and PPARα protein expressions. Thus, our study demonstrated the beneficial effect of SC seed extract on IR and β-cell dysfunction in HFD-STZ-induced type 2 diabetic rats.

MeSH terms

  • Animals
  • Antioxidants / metabolism
  • Blood Glucose / metabolism
  • Catalase / metabolism
  • Diabetes Mellitus, Experimental / drug therapy
  • Diabetes Mellitus, Experimental / metabolism
  • Diabetes Mellitus, Type 2 / blood
  • Diabetes Mellitus, Type 2 / drug therapy*
  • Diabetes Mellitus, Type 2 / metabolism
  • Dyslipidemias / drug therapy*
  • Dyslipidemias / metabolism
  • Female
  • Glutathione Peroxidase / metabolism
  • Homeostasis / drug effects
  • Hyperglycemia / drug therapy
  • Hyperglycemia / metabolism
  • Hypoglycemic Agents / pharmacology
  • Insulin / blood
  • Insulin Resistance
  • Insulin-Secreting Cells / drug effects
  • Insulin-Secreting Cells / metabolism
  • Islets of Langerhans / drug effects
  • Islets of Langerhans / metabolism
  • Lipids / blood
  • Male
  • Oxidative Stress / drug effects*
  • Pancreas / drug effects
  • Peroxisome Proliferator-Activated Receptors / metabolism*
  • Plant Extracts / pharmacology*
  • Rats
  • Rats, Wistar
  • Seeds / chemistry
  • Streptozocin / pharmacology
  • Superoxide Dismutase / metabolism
  • Syzygium / chemistry*
  • Thiobarbituric Acid Reactive Substances / metabolism
  • Tumor Necrosis Factor-alpha / blood*
  • Tumor Necrosis Factor-alpha / metabolism

Substances

  • Antioxidants
  • Blood Glucose
  • Hypoglycemic Agents
  • Insulin
  • Lipids
  • Peroxisome Proliferator-Activated Receptors
  • Plant Extracts
  • Thiobarbituric Acid Reactive Substances
  • Tumor Necrosis Factor-alpha
  • Streptozocin
  • Catalase
  • Glutathione Peroxidase
  • Superoxide Dismutase